# US 2001/0024831 A1 · Intrabodies with defined framework that is stable in a reducing environment and applications thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024831 A1
- Document ID: US20010024831A1
- Status: Published application
- Kind: A1
- Application number: 09/750,424
- Filed: 2000-12-28
- Published: 2001-09-27
- Earliest claimed: 1999-12-28
- Assignees: ESBATech AG
- Inventors: Adrian Auf Der Maur; Alcide Barberis; Dominik Escher
- Web page: https://patentgrep.com/patent/US20010024831A1

## CPC

- C07K 16/005: {constructed by phage libraries}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/14: against material from fungi, algea or lichens
- C12N 15/1055: {Protein x Protein interaction, e.g. two hybrid selection}
- C12N 15/1093: {General methods of preparing gene libraries, not provided for in other subgroups}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/80: remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
- C07K 2318/10: Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for the isolation of CDRs in a defined framework that is stable and soluble in reducing environment is described as well as thus obtainable scFv. Starting from such scFv with defined framework a scFv library can be generated wherein the framework is conserved while at least one complementary determining region (CDR) is randomized. Such library, e.g. in yeast cells, is suitable for screening for antibody/CDR-interactions or for screening for antibodies.

## Claims

### Claim 1

A method for the isolation of an scFv with defined framework that is stable and soluble in a reducing environment, wherein
a) a scFv library with varied frameworks and constant CDRs is generated by mutation of at least one framework encoding region of DNA sequence of a scFv to a known antigen and by introduction of such mutations into suitable expression vectors,
b) host cells able to express a specific known antigen and only surviving in the presence of antigen-scFv-interaction are transformed with said scFv library,
c) the thus transformed host cells are cultivated under conditions suitable to express the antigen and the scFv and allowing cell survival only in the presence of antigen-scFv-interaction,
d) the scFv expressed in surviving cells and having a defined framework that is stable and soluble in reducing environment is isolated.

### Claim 2 (depends on 1)

The method of claim 1, wherein the host cell is an eukaryotic cell.

### Claim 3 (depends on 2)

The method of claim 2 wherein the host cell is a yeast cell.

### Claim 4 (depends on 1)

A scFv with defined framework, obtainable by the method of claim 1.

### Claim 5 (depends on 4)

The scFv of claim 4 comprising restriction sites allowing the selective exchanging of at least one CDR.

### Claim 6 (depends on 5)

The scFv of claim 5, wherein the restriction sites are located within the framework flanking a CDR.

### Claim 7

A method for the generation of a scFv encoding DNA with a framework suitable for selective alterations in the CDR region, wherein specific restriction sites are introduced into the sequence of a defined, stable and soluble scFv encoding DNA by means of site directed mutagenesis.

### Claim 8 (depends on 7)

The method of claim 7, wherein the restriction sites are located within the framework and whereby the substitution of the nucleotides to generate the restriction site does not affect the amino acid sequence.

### Claim 9 (depends on 1)

A method for the generation of a scFv with defined framework that is stable and soluble in a reducing environment, wherein at least two variations of at least two different frameworks isolated according to claim 1 that are stable and soluble in a reducing environment are combined to produce a scFv with defined framework.

### Claim 10 (depends on 9)

A scFv with defined framework, obtainable by the method of claim 9.

### Claim 11 (depends on 10)

The scFv of claim 10 wherein the variations are preceding the CDR1 of the variable light chain.

### Claim 12 (depends on 10)

The scFv of claim 10 wherein the variations are located between CDR2 and CDR3 of the variable heavy chain.

### Claim 13 (depends on 10)

The scFv of claim 10 wherein at least one variation is preceding the CDR1 and at least one variation is located between CDR2 and CDR3 of the variable heavy chain.

### Claim 14 (depends on 10)

The scFv of claim 10 wherein at least 2 variations are preceding CDR1 and at least 2 variations are located between CDR2 and CDR3 of the variable heavy chain.

### Claim 15

A scFv comprising the framework defined in SEQ ID NO 1.

### Claim 16

A method for the generation of a CDR library with a defined framework, that is stable and soluble in a reducing environment, wherein DNA sequences encoding a scFv of one of the previous claims are digested to replace at least one CDR per sequence by a modified CDR.

### Claim 17 (depends on 16)

The method of claim 16, wherein the modified CDR is generated by random changes.

### Claim 18

A library of intrabodies with at least one randomized CDR and defined framework that is stable and soluble under reductive conditions.

### Claim 19

A method for screening for CDRs interacting with a specific antigen, wherein host cells transformed with a nucleic acid sequence encoding a known antigen are further transformed with a randomized CDR library with defined framework that is stable and soluble in a reducing environment, whereby the antigen and/or the scFv are linked to a marker system or part of a marker system thus that the cell cultured under selective conditions only survives in the presence of antigen/scFv-interaction, that thus transformed cells are cultivated under selective conditions, and that surviving cells are cultured and the intrabodies harvested.

### Claim 20 (depends on 19)

The method of claim 19, wherein the framework is a framework as defined in one of the preceding claims.

### Claim 21 (depends on 19)

The method of claim 19, wherein the cell is an eukaryotic cell.

### Claim 22 (depends on 19)

The method of claim 19 wherein the DNA sequence encoding the antigen and the DNA sequence encoding the scFv both encode chimeric molecules with the antigen or scFv, respectively, both linked to part of a transcription activating system linked to a survival allowing marker.

### Claim 23 (depends on 22)

The method of claim 22, wherein the antigen is fused to a DNA binding domain and the scFv is fused to a transcriptional activator domain or the antigen is fused to a transcriptional activator domain and the scFv is fused to a DNA binding domain.

### Claim 24

A method for screening for an antigen interacting with an scFv, wherein host cells expressing at least one antigen of interest are transformed with at least one scFv with defined framework that is stable and soluble in reducing environment, or with a randomized CDR library with defined framework that is stable and soluble in reducing environment, whereby the antigens and/or the scFvs are linked to a marker system or part of a marker system thus that the cell cultured under selective conditions only survives in the presence of antigen/scFv-interaction, that thus transformed cells are cultivated under selective conditions, and that surviving cells are cultured and the scFvs harvested.

### Claim 25 (depends on 24)

The method of claim 24, wherein the framework is a framework as defined in one of the preceding claims.

### Claim 26 (depends on 24)

The method of claim 24, wherein the cell is an eukaryotic cell, in particular a yeast cell.

### Claim 27 (depends on 24)

The method of claim 24, wherein the DNA sequence encoding the antigen and the DNA sequence encoding the scFv both encode chimeric molecules with the antigen or scFv, respectively, both linked to part of a transcription activating system linked to a survival allowing marker.

### Claim 28 (depends on 27)

The method of claim 27, wherein the antigen is fused to a DNA binding domain and the scFv is fused to a transcriptional activator domain or the antigen is fused to a transcriptional activator domain and the scFv is fused to a DNA binding domain.

### Claim 29

An scFv with defined framework as therapeutic or diagnostic or prophylactic agent.

### Claim 30

Use of the scFv with defined framework for intracellular screenings.

### Claim 31

A method for the identification of intrabody frameworks or intrabodies wherein suitable host cells are transformed with a library and a marker system, whereby said library is a fusion product of an intrabody library and at least part of said marker system, wherein said marker system is only activated in the presence of a fusion protein encoding a soluble and stable intrabody framework, and culturing said cells under conditions allowing the identification and selection of cells expressing a soluble and stable intrabody framework.

### Claim 32 (depends on 31)

The method of claim 31, wherein said library is a fusion product of an intrabody library and a marker protein.

### Claim 33 (depends on 32)

The method of claim 32, wherein said marker protein has a selectable activity.

### Claim 34 (depends on 33)

The method of claim 33, wherein said selectable activity is an enzymatic activity or a fluorescene activity.

### Claim 35 (depends on 31)

The method of claim 31, wherein said library is a fusion product of an intrabody library and a DNA binding protein that can activate transcription.

### Claim 36 (depends on 31)

The method of claim 31, wherein said suitable host cells are transformed with a library that encodes proteins comprising an intrabody and one part of a transactivation system and said cells further express a second protein comprising the second part of said transactivation system, whereby said transactivation system is linked to a survival allowing marker and said cells only survive under selective conditions in the presence of an interaction between said two proteins.

### Claim 37 (depends on 36)

The method of claim 36, wherein said library encoded proteins comprise a transcriptional activation domain and said second proteins comprise a DNA binding domain or said library encoded proteins comprise a DNA binding domain and said second proteins comprise a transcriptional activation domain.

### Claim 38 (depends on 37)

The method of claim 37, wherein said second proteins comprise a DNA binding domain or a transactivation domain, respectively, and a protein interacting with a constant region of said first library encoded protein.

### Claim 39 (depends on 31)

A scFv with defined framework obtainable by the method of claim 31.

### Claim 40 (depends on 19)

The method of claim 19, wherein the nucleic acid sequence is a DNA sequence.

### Claim 41 (depends on 21)

The method of claim 21 wherein the eukaryotic cell is a yeast cell.
